Pediatric Clinical Pharmacology in Regulatory and Drug Development Sciences: Lessons Learned and the Path Forward

2013 ◽  
pp. 271-280
Author(s):  
Gilbert J. Burckart ◽  
Jeremiah D. Momper
Author(s):  
Gina Pastino ◽  
Diana Shuster

The use and acceptance of cannabis, either medically or recreationally, has substantially outpaced the collection of data necessary to evaluate its use in any population. However, the mere widespread availability does not imply the absence of risk or confirmation of efficacy and should not be treated as such. There is enough data to suggest that not only does the potential for pharmacokinetic and metabolic interactions exist, but also that baseline characteristics for a given population could be different in chronic cannabis users. Either or both of these may impact the safety and efficacy profile for any new drug in development. As such, we encourage drug developers to consider that the cannabis user may very well be a special population that warrants its own clinical pharmacology evaluation.


Author(s):  
Bilal Abuasal ◽  
Mariam A. Ahmed ◽  
Priyank Patel ◽  
Salwa Albusaysi ◽  
Sreedharan Sabarinath ◽  
...  

2017 ◽  
Vol 23 (6) ◽  
pp. 425-430 ◽  
Author(s):  
SHELDON H. PRESKORN

2021 ◽  
pp. 243-256
Author(s):  
Ann-Charlotte Egnell ◽  
Susanne Johansson ◽  
Chao Chen ◽  
Alienor Berges

2020 ◽  
Vol 108 (4) ◽  
pp. 710-715
Author(s):  
Rajanikanth Madabushi ◽  
Elimika Pfuma Fletcher ◽  
Jeffry Florian ◽  
Lauren Milligan ◽  
Anuradha Ramamoorthy ◽  
...  

2019 ◽  
Vol 46 (5) ◽  
pp. 395-409 ◽  
Author(s):  
Mariam A. Ahmed ◽  
Malek Okour ◽  
Richard Brundage ◽  
Reena V. Kartha

Sign in / Sign up

Export Citation Format

Share Document